Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Montalescot G, et al. Among authors: bode c. N Engl J Med. 2006 Sep 7;355(10):1006-17. doi: 10.1056/NEJMoa052711. N Engl J Med. 2006. PMID: 16957147 Free article. Clinical Trial.
Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J; SEPIA-PCI Trial Investigators. Cohen M, et al. Among authors: bode c. Circulation. 2007 May 22;115(20):2642-51. doi: 10.1161/CIRCULATIONAHA.106.653428. Epub 2007 May 14. Circulation. 2007. PMID: 17502577 Clinical Trial.
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Steinhubl S, Montalescot G. White HD, et al. Among authors: bode c. Am Heart J. 2009 Jan;157(1):125-31. doi: 10.1016/j.ahj.2008.08.019. Epub 2008 Nov 12. Am Heart J. 2009. PMID: 19081408 Clinical Trial.
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Giugliano RP, et al. Among authors: bode c. N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30. N Engl J Med. 2009. PMID: 19332455 Free article. Clinical Trial.
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Montalescot G, et al. Among authors: bode c. JACC Cardiovasc Interv. 2009 Nov;2(11):1083-91. doi: 10.1016/j.jcin.2009.08.016. JACC Cardiovasc Interv. 2009. PMID: 19926048 Free article. Clinical Trial.
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD, Aylward PE, Gallo R, Bode C, Steg G, Steinhubl SR, Montalescot G; STEEPLE Investigators. White HD, et al. Among authors: bode c. Am Heart J. 2010 Jan;159(1):110-6. doi: 10.1016/j.ahj.2009.10.034. Am Heart J. 2010. PMID: 20102875 Clinical Trial.
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.
Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH. Povsic TJ, et al. Among authors: bode c. Am Heart J. 2011 Feb;161(2):261-268.e1-2. doi: 10.1016/j.ahj.2010.10.022. Am Heart J. 2011. PMID: 21315207 Clinical Trial.
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.
Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators. Gibson CM, et al. Among authors: bode c. Eur Heart J. 2024 Dec 16;45(47):5023-5038. doi: 10.1093/eurheartj/ehae614. Eur Heart J. 2024. PMID: 39221651 Clinical Trial.
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Lincoff AM, et al. Among authors: bode c. JAMA. 2002 Nov 6;288(17):2130-5. doi: 10.1001/jama.288.17.2130. JAMA. 2002. PMID: 12413372 Clinical Trial.
1,402 results